

POCKET NO.: CELL-0296

PATENT

PUT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Helene Margaret Finney, et al.

Confirmation No.: Not Yet Assigned

Application No.: 10/533,003

Group Art Unit: Not Yet Assigned

Filing Date: April 28, 2005

Examiner: Not Yet Assigned

For: CHIMERIC CYTOPLASMIC SIGNALLING MOLECULES

DATE OF DEPOSIT July 18, 2005

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,

VA 22313-1450

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

	the above identified application as set forth in § 1.491, before the mailing date
	of a first Office Action on the merits of the above-identified application, or
	before the mailing date of a first Office Action after the filing of request for
	continued examination under § 1.114, no additional fee is required.
	In accordance with § 1.97(c), this Information Disclosure Statement is being
	filed after the period set forth in § 1.97(b) above but before the mailing date of
	either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or
	before an action that otherwise closes prosecution in the application, therefore:
	Certification in Accordance with § 1.97(e) is attached; or
	The fee of $$180.00$ as set forth in § 1.17(p) is attached.
	In accordance with § 1.97(d), this Information Disclosure Statement is being
	filed after the mailing date of either a Final Action under § 1.113 or a Notice
	of Allowance under § 1.311 but before, or simultaneously with, the payment
	of the Issue Fee, therefore included are: Certification in Accordance with §
	1.97(e); and the submission fee of <u>\$180.00</u> as set forth in § 1.17(p).
\boxtimes	Copies of reference numbers 1 - 42 listed on the attached Form PTO-1449 are
	enclosed herewith.
	Copies of reference numbers - on the attached Form PTO 1449
	are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).
	Copies of references - are not being submitted because
	they were previously cited by or submitted to the U.S. Patent and
	Trademark Office in patent application number , filed for
	which a claim for priority under 35 U.S.C. § 120 has been made in the
	instant application.

DOC	KET NO.: CELL-0296	- 3 -	PATENT
	The relevance of those listed refere follows:	nces which are not in the English	language is as
	There are no listed references which	are not in the English language.	
	Please charge any deficiency or cree	dit any overpayment to Deposit A	ccount No. 23-
3050.	This form is submitted in duplicate.		
Date:	July 15, 2005	Jane E. Inglese	
WOO	DCOCK WASHBURN LLP	Registration No. 48,444	

One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2005 WW

List of Pate Cited (Use several U.S. Depare	Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Application No. 10/533,003 ey, et al. Group Not Yet Assigned				
ОТН	ER DOCUMENTS (Inclu	Not Yet Assigned	Partinent Pages Ftc)				
		ng tumor-specific T-cell					
	1	ing tumor-specific 1-cent in Immunol., England, 2					
			uncertainties of a prevalent human				
		& Cell Biol., 2002 , 80, 1-					
		Aruffo, A., et al., "Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system," <i>Proc. of the Nat. Acad. Sci. USA</i> , 1987 , <i>84</i> , 8573-8577					
		Burshytn, D.N., et al., "Conserved residues amino-terminal of cytoplasmic tyrosines contribute to the SHP-1-mediated inhibitory function of killer cell Ig-Like receptors,"					
	J. of Immunol., 1999, 16	J. of Immunol., 1999, 162, 897-902					
5		Carreno, B.M., et al., "The B7 family of ligands and its receptors: New pathways for					
		costimulation and inhibition of immune responses," Annu. Rev. Immunol., 2002, 20,					
		29-53 Chambers, C.A., "The expanding world of co-stimulation: the two-signal model					
`		revisited," Trends in Immunol., Cambridge, 2001, 22(4), 217-223					
7		DeFranco, A.L., "The complexity of signaling pathways activated by the BCR,"					
		Curr. Opin. In Immunol., 1997, 9, 296-308					
8		Eshar, Z., et al., "Functional expression of chimeric receptor genes in human T					
	cells," J. of Immunol. Methods, 2001, 248, 67-76						
9		Finney, H.M., et al., "Chimeric receptors providing both primary and costimulatory					
	signaling in T cells from a single gene product," J. of Immunol., 1998, 161, 2791-2797						
10		Hombach, A., et al., "Tumor-specific T cell activation by recombinant					
		immunoreceptors: CD3\xi signaling and CD2\xi costimulation are simultaneously					
		required for efficient IL-2 secretion and can be integrated into one combined					
	DC28/CD3ξ signaling receptor molecule," J. of Immunol., 2001, 167, 6123-6131						
EXAMINER		DATE CO	NSIDERED				

Form PTO-1449 M	Docket No CELL-029 PA524-US	6/	Application No. 10/533,003			
List of Patent and Publ Cited by Applica (Use several sheets if ne	Applicant Helene Margaret Finney, et al.					
	U.S. Department of Commerce Patent and Trademark Office			Group Not Yet Assigned		
		Confirmati Not Yet As				
OTHER DOCUM	MENTS (Includ	ing Author,	Title, Date, 1	Pertinent Pages, Etc.)		
functiona	ally related to Cl	D28," Natur	e, 1999 , 397, 2			
	munogenicity a			40 receptor antibody depends on growth," Cancer Res., 2000, 60,		
derived \	Kuwana, Y., et al., "Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions," <i>Biochem. & Biophys. Res. Commun.</i> , 1987, 149(3), 960-968					
14 Latza, U.	Latza, U., et al., "The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen," Eur. J. of Immunol., 1994, 24,					
	Maher, J., et al., "Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRξ/CD28 receptor," <i>Nat. Biotech.</i> , 2002 , <i>20</i> , 70-75					
actively	Miller, D.G., et al., "Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection," <i>Mol. & Cell. Biol.</i> , 1990, 10(8), 4239-4242					
identical of Immun	Moingeon, P., et al., "Human natural killer cells and mature T lymphocytes express identical CD3 ξ subunits as defined by cDNA cloning and sequence analysis," <i>Eur. J. of Immunol.</i> , 1990 , <i>20</i> , 1741-1745					
binding of and IL-2 Baltimor	Parry, R.V., et al., "CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bc1-xL, and IL-2 expression in primary human CD4 T lymphocytes," <i>J. of Immunol.</i> , <i>Baltimore</i> , 2003 , <i>171(1)</i> , 166-174					
19 Reth, M.	, "Antigen recep	otor tail clue,	" Nature, 198	9, 338, 383-384		
	Rogers, P.R., et al., "OX40 promotes Bc1-xL and Bc1-2 expression and is essential for long-term survival of CD4 T cells," <i>Immunity, US</i> , 2001, 15(3), 445-455					
EXAMINER			DATE CONS	SIDERED		

List of C (Use sev U.S. De	Paten lited b veral s	t and Publications y Applicant sheets if necessary) nent of Commerce Trademark Office	Docket No CELL-029 PA524-US Applicant Helene Modern Filing Dat April 28, 2 Confirmat Not Yet A	Sw01 argaret Finney, e 2005 ion No.	Application No. 10/533,003 et al. Group Not Yet Assigned	
O 7	ГНЕ	R DOCUMENTS (Includ	ing Author	, Title, Date, I	Pertinent Pages, Etc.)	
	21		nains," <u>Col</u>		fector function by T-cell or Fc ur Symposia on Quantitative	
	22	Shulford, W.W., et al., "4- 1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses," J. of Exper. Med., Tokyo, 1997, 186(1), 47-55				
	23				te antigen receptors," Cell, 1994,	
	24				romosomal localization of the molecular CD3 complex," PNAS,	
		·				
EXAMINER				DATE CONS	SIDERED	

Docket No. Application No. Form PTO-1449 Modified CELL-0296/ 10/533,003 PA524-USw01 List of Patent and Publications Cited by Applicant Applicant Helene Margaret Finney, et al. (Use several sheets if necessary) U.S. Department of Commerce Filing Date Group Patent and Trademark Office April 28, 2005 Not Yet Assigned Confirmation No. Not Yet Assigned FOREIGN PATENT DOCUMENTS Examiner Translation Initial Document No. Date Country YES NO 25 WO 88/04924 A1 07/14/88 **PCT** 26 WO 90/09782 A1 09/07/90 **PCT PCT** WO 91/05545 A1 05/02/91 27 **PCT** WO 91/05546 A1 05/02/91 28 **PCT** 10/14/93 29 WO 93/19738 A1 **PCT** 09/15/94 **30** WO 94/20073 A1 PCT WO 94/22429 A1 10/13/94 31 PCT 32 WO 96/10038 A1 -04/04/96 **PCT** 33 WO 96/23814 A1 ² 08/08/96 **PCT** 08/15/96 34 WO 96/24671 A1 PCT X abstract 05/22/97 35 WO 97/18185 A1 **PCT** WO 97/23613 A3 07/03/97 36 PCT 07/17/97 WO 97/25329 A1 37 PCT WO 97/30170 A1 08/21/97 38 **PCT** 39 WO 97/31934 A3° 09/04/97

DATE CONSIDERED

EXAMINER

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary)				Docket No. CELL-0296/ PA524-USw01 Application No. 10/533,003 Applicant Helene Margaret Finney, et al.			
				Confirmation No. Not Yet Assigned			
		FORE	IGN PATI	ENT DOCUMENTS			
Examiner		Document No.	Date	Translatio			
Initial	40	WO 99/00494 A3	01/07/99	Country PCT		YES	NO
	41	WO 99/57268 A1 '	11/11/99	PCT			
	42	WO 02/33101 A1	04/25/02	PCT			
			0 11 20, 02				
					-		
, , , , , , , , , , , , , , , , , , , ,					,		
EXAMINER			DATE CONSIDER	RED			